Targeted Nanoparticles for Vascular Stenosis and AVF Failure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vascular disorders such as arteriovenous fistula (AVF) failure, stenosis, and atherosclerosis are inadequate, with high failure rates and no marketed drugs effectively addressing AVF failure, and existing therapies for atherosclerosis come with complications like in-stent restenosis and late stent thrombosis.
Innovation Solution
Development of targeted nanoparticles comprising an inhibitor of microRNA-92a (miR-92a) using polyelectrolyte micelles with a PEG domain and positively charged amino acids, specifically targeting inflamed endothelial cells to reduce inflammation and promote vascular health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (anti-platelet agents, anti-coagulant drugs, antihypertensive drugs) are used for AVF failure, then standard care is provided, but there is no clinically meaningful benefit in reducing AVF failure
Solution Approach 1:
The patent changes the molecular target parameter from conventional drug classes to microRNA-92a inhibition. By using nanoparticle-delivered anti-miR-92a oligonucleotides, the treatment mechanism fundamentally shifts from traditional vascular protection to specific molecular pathway modulation, achieving AVF maturation and durability improvement
Solution Approach 2:
The patent introduces nanoparticles as an intermediary delivery system. These nanoparticles carry the anti-miR-92a oligonucleotides to the target site (AVF), serving as a mediator that enables precise delivery of the molecular therapy while overcoming the limitations of conventional drug administration
2Reliability
If drug-eluting stents are used for atherosclerosis treatment, then stenosis is reduced, but very late stent thrombosis occurs as a catastrophic complication
Solution Approach 1:
The patent extracts the therapeutic action from the stent structure itself and delivers it via circulating nanoparticles. Instead of relying on drug elution from the stent surface (which causes thrombosis), the system uses nanoparticle-delivered anti-miR-92a oligonucleotides that act systemically and specifically at the site of need, removing the source of thrombotic risk
Solution Approach 2:
The patent replaces the mechanical drug-eluting stent system with a molecular therapy system. Rather than using physical stent structures with embedded drugs, the treatment uses nanoparticle-carried oligonucleotides that modulate gene expression at the cellular level, substituting mechanical intervention with molecular mechanism
3Reliability
If percutaneous coronary intervention with stenting is performed, then coronary artery blockage is treated, but in-stent restenosis occurs due to neointimal hyperplasia
Solution Approach 1:
The patent applies preliminary action by preventing restenosis before it occurs. The nanoparticle-delivered anti-miR-92a oligonucleotides are administered prior to or at the time of stent placement, proactively inhibiting the molecular pathways that lead to neointimal hyperplasia and restenosis, rather than reacting after the problem develops
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles effectively reduce vascular stenosis, enhance AVF maturation, and decrease atherosclerotic lesion formation, offering a novel approach to treating vascular disorders with improved efficacy and reduced side effects.
Implementation Method 1
Micelles are nanoparticles formed, for example, by self-assembly of amphiphilic block copolymers with a hydrophobic core
Implementation Method 2
The targeting molecule can include a peptide such as VHPKQHR, which has been shown to facilitate binding to vascular cell adhesion molecule 1 (VCAM-1) on the surface of endothelial cells
Implementation Method 3
displaying targeting capabilities to facilitate cell binding and internalization
Data Source
AI summary
This disclosure relates to compositions and methods for treating vascular disorders, including, for example, arteriovenous fistula (AVF) failure, stenosis, restenosis, and atherosclerosis.